Dulaglutide Market Report 2026

The dulaglutide market size has grown strongly in recent years. It will grow from $4.47 billion in 2025 to $4.8 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to type 2 diabetes prevalence growth, insulin therapy limitations, glp-1 clinical success, injectable device innovation, endocrinology guideline updates.

The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $6.42 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to obesity-diabetes overlap treatment, long-acting formulation innovation, biosimilar development, digital diabetes management tools, emerging market access. Major trends in the forecast period include rising adoption of glp-1 receptor agonists, growing preference for once-weekly injectable therapies, expansion of diabetes combination treatment approaches, increasing use in cardiometabolic risk management, growth of patient adherence support programs.

The rising prevalence of type 2 diabetes is expected to drive the growth of the dulaglutide market in the coming years. Type 2 diabetes is a chronic disorder in which the body either becomes resistant to insulin or fails to produce sufficient insulin, resulting in elevated blood sugar levels. The increase in type 2 diabetes is largely driven by higher rates of obesity, unhealthy diets, and sedentary lifestyles. Dulaglutide aids in managing type 2 diabetes by boosting insulin secretion and reducing glucagon levels in response to food intake, thereby lowering blood sugar. For instance, in April 2023, according to a report by The British Diabetic Association, a UK-based diabetes charity, 4.3 million people in the UK have diabetes, and over 2.4 million are at high risk of developing type 2 diabetes, with registration numbers for 2021-22 increasing by 148,951. Therefore, the growing prevalence of type 2 diabetes is propelling the growth of the dulaglutide market.

Major companies in the dulaglutide market are focusing on developing innovative anti-diabetic drugs to meet the rising demand for effective diabetes treatments. Anti-diabetic drugs are medications that help manage diabetes mellitus by regulating blood sugar levels through mechanisms such as enhancing insulin sensitivity, stimulating insulin production, or slowing glucose absorption from the digestive system. For instance, in January 2024, Glenmark Pharmaceuticals Limited, an India-based pharmaceutical company, launched India’s first biosimilar of the anti-diabetic drug Liraglutide under the brand name Lirafit. This launch marks Glenmark’s strategic entry into the biosimilar anti-diabetic market, aiming to provide patients with a more affordable treatment option. The biosimilar is expected to maintain efficacy and safety profiles comparable to the original drug, meeting rigorous regulatory standards.

In August 2023, Lupin Limited, an India-based pharmaceutical company, acquired two diabetic brands from Boehringer Ingelheim for €26 million ($28 million). Through this acquisition, Lupin seeks to strengthen its position in the diabetes care market by expanding its product portfolio and enhancing its presence in diabetes management. Boehringer Ingelheim is a Germany-based company engaged in the development and marketing of dulaglutide, a medication used to treat type 2 diabetes.

Major companies operating in the dulaglutide market are Merck And Co. Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Cipla Limited, Intas Pharmaceuticals Limited, Biocon Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Insulet Corporation, Nicholas Piramal India Limited, IPCA Laboratories Limited, Alembic Pharmaceuticals Limited, Ypsomed Holding AG, Wockhardt Limited, MannKind Corporation, Bioton S.A., Midas Pharma GmbH, Senova Technology Co. Ltd., Enomark.

North America was the largest region in the dulaglutide market in 2025. The regions covered in the dulaglutide market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dulaglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the dulaglutide market by increasing costs of imported active pharmaceutical ingredients, injectable devices, and cold-chain packaging materials. Pharmaceutical manufacturers and hospital pharmacies in developed markets are most affected. These tariffs raise drug prices by increasing production, packaging, and distribution expenses for injectable diabetes therapies, placing cost pressure on healthcare systems and patients. However, they promote domestic API production and local manufacturing of injectable delivery systems, encouraging regional self-sufficiency in biologics manufacturing and strengthening cold-chain infrastructure over the long term.

The dulaglutide market research report is one of a series of new reports that provides dulaglutide market statistics, including dulaglutide industry global market size, regional shares, competitors with a dulaglutide market share, detailed dulaglutide market segments, market trends and opportunities, and any further data you may need to thrive in the dulaglutide industry. This dulaglutide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Dulaglutide is a medication used to control blood sugar levels in individuals with type 2 diabetes. It is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics the action of the natural hormone GLP-1. Dulaglutide is typically administered once a week via subcutaneous injection.

The main forms of dulaglutide are syringe pens and multi-dose bottles. A syringe pen is a device designed for injecting medications like dulaglutide, combining the medication and needle into a single, compact, and easy-to-use tool. It allows patients to adjust the dosage, providing convenience for precise administration. Applications include medical insurance, pharmaceutical use, and clinical research, with distribution through hospital pharmacies, retail pharmacies, and online pharmacies.

The dulaglutide market consists of sales of blood glucose monitors, needles, and injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.